Psoas compartment block for treatment of motor weakness and pain following herpes zoster

Kim, Sae Young; Kim, Dong Gyeong; Park, Yong Mean; Jeon, Young Hoon

doi:10.3344/kjp.2017.30.1.62

Cited by 5 publications

(3 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[13] Administration of steroid around injured nerve may alleviate edema and provide analgesia through its anti-inflammatory and membrane stabilising actions, lead to hastening recovery of the damaged nerves. [14,15] …”

Section: Discussionmentioning

confidence: 99%

Treatment of great auricular neuralgia with real-time ultrasound-guided great auricular nerve block

Jeon

Kim²

2017

Medicine

View full text Add to dashboard Cite

Rationale:The great auricular nerve can be damaged by the neck surgery, tumor, and long-time pressure on the neck. But, great auricular neuralgia is very rare condition. It was managed by several medication and landmark-based great auricular nerve block with poor prognosis.Patient concerns:A 25-year-old man presented with a pain in the left lateral neck and auricle.Diagnosis:He was diagnosed with great auricular neuralgia.Interventions:His pain was not reduced by medication. Therefore, the great auricular nerve block with local anesthetics and steroid was performed under ultrasound guidance.Outcomes:Ultrasound guided great auricular nerve block alleviated great auricular neuralgia.Lessons:This medication-resistant great auricular neuralgia was treated by the ultrasound guided great auricular nerve block with local anesthetic agent and steroid. Therefore, great auricular nerve block can be a good treatment option of medication resistant great auricular neuralgia.

show abstract

Section: Discussionmentioning

confidence: 99%

Treatment of great auricular neuralgia with real-time ultrasound-guided great auricular nerve block

Jeon

Kim²

2017

Medicine

View full text Add to dashboard Cite

show abstract

“…The involvement of C3-C5 motor nerves could lead to diaphragmatic paresis and induce the clinical manifestations, including dyspnea and pulmonary dysfunction (42,43). The affected ganglion segments and possible clinical manifestation are summarized in Table 1 (3,7,28,34,(44)(45)(46)(47)(48)(49)(50)(51)(52)(53)(54)(55)(56)(57)(58)(59)(60)(61)(62)(63).…”

Section: Clinical Characteristics Of Szpmentioning

confidence: 99%

Segmental Zoster Paresis: A Literature Review

et al. 2021

View full text Add to dashboard Cite

Background: Herpes zoster is an acute infectious skin disease that is induced by the re-activation of the virus incubated in nerve ganglions following initial infection with varicella-zoster virus in childhood. Herpes zoster mainly affects sensory nerves, resulting in severe acute pain, which is also the most common reason for medical intervention in this patient group. The concurrent involvement of motor nerves could induce the symptoms of segmental zoster paresis, which is manifested by localized asymmetric myasthenia, whose range generally follows the distribution of myomere with skin rashes. Due to the low incidence and unspecific clinical manifestations, segmental zoster paresis has not been sufficiently recognized by clinicians, and can easily be misdiagnosed. Objective: To summarize the previous studies on segmental zoster paresis and analyze the pathogeneses, diagnosis, and treatment of this disease, as well as stress the challenges in current treatment, which could provide useful evidence for the clinical diagnosis and better the treatment of patients with segmental zoster paresis in the future. Study Design: We conducted a narrative review. Setting: Hospitals, neurology departments, pain departments, and private practices. Methods: We searched PubMed and Chinese CNKI libraries using the terms “herpes zoster,” “muscle paresis,” “segmental zoster paresis,” and “motor nerve.” Clinical trials, reviews, and case reports were collected and reviewed. Results: As a rare complication following varicella-zoster virus infection, segmental zoster paresis has not been sufficiently recognized by clinicians, and there are still no guidelines available to guide the clinical treatments. The exact mechanism of segmental zoster paresis is still unclear. Electromyographic and magnetic resonance imaging examinations could be used as auxiliary diagnostic methods for segmental zoster paresis. Early regular anti-viral therapy could substantially decrease the risk of herpes zoster related complications. Combined application of glucocorticoids and some other physical therapy may also be useful in certain patients. The general prognosis of segmental zoster paresis is relatively good, with 67% patients achieving complete or almost complete recovery of the muscle function. Limitations: More clinical trials are needed to clarify the exact mechanisms and best treating methods. Conclusion: As the symptom in most segmental zoster paresis patients is self-limited, and the patients’ prognosis is generally good, early diagnosis of the disease is especially important, due to the avoidance of unnecessary diagnostic procedures and incorrect treatments. Standard treatment guidelines regarding the functional rehabilitation are still needed for patients with refractory segmental zoster paresis. Key words: Herpes zoster, postherpetic neuralgia, segmental zoster paresis, muscle strength, motor nerve, spinal dorsal ganglion, zoster infection, muscle paresis

show abstract

“…The replicated latent VZV leads to inflammatory sensory or motor neural damage of the peripheral and central nervous systems, resulting in zoster-associated pain (ZAP) or postherpetic neuralgia (PHN) [ 1 , 11 ]. In addition to the therapeutic effect of antivirals on HZ itself, the reduction and prevention of ZAP or PHN are also important clinical perspectives [ 1 , 12 , 13 ].…”

Section: Introductionmentioning

confidence: 99%

Current scenario and future applicability of antivirals against herpes zoster

Kim

2023

Korean J Pain

View full text Add to dashboard Cite

Herpes zoster (HZ) is a common disease in the aging population and immunocompromised individuals, with a lifetime risk of 20%-30% that increases with age. HZ is caused by reactivation of the varicella-zoster virus (VZV), which remains latent in the spinal dorsal root ganglia and cranial sensory ganglia after resolution of the primary VZV infection. The main focus of HZ management is rapid recovery from VZV infection as well as the reduction and prevention of zoster-associated pain (ZAP) and postherpetic neuralgia (PHN). The use of antivirals against VZV is essential in the treatment of HZ. However, limited antivirals are only licensed clinically for the treatment of HZ, including acyclovir, valacyclovir, famciclovir, brivudine, and amenamevir. Fortunately, some new antivirals against different types of Herpesviridae have been investigated and suggested as novel drugs against VZV. Therefore, this review focuses on discussing the difference in efficacy and safety in the currently licensed antivirals for the treatment of HZ, the applicability of future novel antivirals against VZV, and the preventive or therapeutic effects of these antivirals on ZAP or PHN.

show abstract

Psoas compartment block for treatment of motor weakness and pain following herpes zoster

Cited by 5 publications

References 17 publications

Treatment of great auricular neuralgia with real-time ultrasound-guided great auricular nerve block

Treatment of great auricular neuralgia with real-time ultrasound-guided great auricular nerve block

Segmental Zoster Paresis: A Literature Review

Current scenario and future applicability of antivirals against herpes zoster

Contact Info

Product

Resources

About